 | |
 Quinupristin (top) and dalfopristin (bottom) | |
| Combination of | |
|---|---|
| Quinupristin | Streptogramin antibiotic |
| Dalfopristin | Streptogramin antibiotic |
| Clinical data | |
| Pronunciation | kwi NYOO pris tin / dal FOE pris tin |
| Trade names | Synercid |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | IV |
| Drug class | Streptogramin antibiotics[1] |
| Legal status | |
| Legal status |
|
  (what is this?) (verify) | |
Quinupristin/dalfopristin, sold under the brand name Synercid, is a combination of two antibiotics used to treat infections by staphylococci, including Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE).[1] It is not very effective against VRE.[2] It is given by gradual injection into a vein.[1]
Common side effects include pain at the site of injection, nausea, diarrhea, joint and muscle pain, headache, and rash.[1] Other side effects may include Clostridioides difficile infection and anaphylaxis.[1] Quinupristin and dalfopristin are both streptogramin antibiotics, made from from pristinamycin.[1]
The combination was approved for medical use in the United States in 1999.[1] In the United States 10 doses of 350 mg/150 mg costs about 4,900 USD as of 2021.[3] In the United Kingdom it is no longer available as of 2018.[2]
References
edit- ^ a b c d e f g h i "Quinupristin/Dalfopristin Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 20 October 2021.
- ^ a b Barer, Michael R.; Irving, Will L. (13 January 2018). Medical Microbiology E-Book: A Guide to Microbial Infections. Elsevier Health Sciences. p. 53. ISBN 978-0-7020-7198-0. Archived from the original on 21 October 2021. Retrieved 20 October 2021.
- ^ "Synercid Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 November 2020. Retrieved 20 October 2021.